These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7755343)

  • 1. [Hyperaldosteronism suppressible by glucocorticoids. An unusual cause of familial hypertension].
    Pasquet A; Thibaut A; Maiter D; De Plaen JF
    Ann Endocrinol (Paris); 1995; 56(2):149-53. PubMed ID: 7755343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term evolution of glucocorticoid-suppressible hyperaldosteronism.
    Stockigt JR; Scoggins BA
    J Clin Endocrinol Metab; 1987 Jan; 64(1):22-6. PubMed ID: 3536983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary aldosteronism: learning from the study of familial varieties.
    Stowasser M; Gordon RD
    J Hypertens; 2000 Sep; 18(9):1165-76. PubMed ID: 10994747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexamethasone-suppressible hypertension.
    Stewart PM
    Lancet; 2000 Aug; 356(9231):697-9. PubMed ID: 11085685
    [No Abstract]   [Full Text] [Related]  

  • 5. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I.
    Stowasser M; Huggard PR; Rossetti TR; Bachmann AW; Gordon RD
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4031-6. PubMed ID: 10566645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism.
    Ganguly A; Pratt JH; Weinberger MH; Grim CE; Fineberg NS
    J Clin Endocrinol Metab; 1983 Aug; 57(2):388-92. PubMed ID: 6306041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New genetic insights in familial hyperaldosteronism.
    Jackson RV; Lafferty A; Torpy DJ; Stratakis C
    Ann N Y Acad Sci; 2002 Sep; 970():77-88. PubMed ID: 12381543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid remediable aldosteronism: a case report.
    Hsieh CJ; Wang PW; Liu JC; Tung SC; Chien WY; Lu YC; Kuo MC
    Changgeng Yi Xue Za Zhi; 1997 Mar; 20(1):52-7. PubMed ID: 9178594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial hyperaldosteronism.
    Torpy DJ; Stratakis CA; Chrousos GP
    Braz J Med Biol Res; 2000 Oct; 33(10):1149-55. PubMed ID: 11004715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.
    Geller DS; Zhang J; Wisgerhof MV; Shackleton C; Kashgarian M; Lifton RP
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3117-23. PubMed ID: 18505761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperaldosteronism sensitive to dexamethasone with adrenal adenoma. Clinical, biological and genetic study].
    Jeunemaitre X; Charru A; Pascoe L; Guyene TT; Aupetit-Faisant B; Shackleton CH; Schambelan M; Plouin PF; Corvol P
    Presse Med; 1995 Sep; 24(27):1243-8. PubMed ID: 7501605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid-remediable aldosteronism.
    Halperin F; Dluhy RG
    Endocrinol Metab Clin North Am; 2011 Jun; 40(2):333-41, viii. PubMed ID: 21565670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone-suppressible hyperaldosteronism: pathophysiology, clinical aspects, and new insights into the pathogenesis.
    Fallo F; Sonino N; Boscaro M; Armanini D; Mantero F; Dörr HG; Knorr D; Kuhnle U
    Klin Wochenschr; 1987 May; 65(10):437-44. PubMed ID: 3037179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism.
    Fallo F; Pilon C; Williams TA; Sonino N; Morra Di Cella S; Veglio F; De Iasio R; Montanari P; Mulatero P
    J Hum Hypertens; 2004 Jan; 18(1):47-51. PubMed ID: 14688810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone-suppressible hyperaldosteronism: a large new kindred.
    O'Mahony S; Burns A; Murnaghan DJ
    J Hum Hypertens; 1989 Aug; 3(4):255-8. PubMed ID: 2552113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension.
    Stowasser M; Bachmann AW; Huggard PR; Rossetti TR; Gordon RD
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3313-8. PubMed ID: 10999827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents.
    Jamieson A; Inglis GC; Campbell M; Fraser R; Connell JM
    Arch Dis Child; 1994 Jul; 71(1):40-3. PubMed ID: 7915100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression.
    Jamieson A; Slutsker L; Inglis GC; Fraser R; White PC; Connell JM
    Clin Sci (Lond); 1995 May; 88(5):563-70. PubMed ID: 7614815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism.
    Woodland E; Tunny TJ; Hamlet SM; Gordon RD
    Clin Exp Pharmacol Physiol; 1985; 12(3):245-8. PubMed ID: 2992855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism.
    Gill JR; Bartter FC
    J Clin Endocrinol Metab; 1981 Aug; 53(2):331-7. PubMed ID: 6265487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.